🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,071 results for “tablet” Clear

  1. Rimactan 300 mg hörð hylki., Moxifloxacin Tillomed 400 mg film coated tablets, LINEZOLID, RIMSTAR®, COMPRIMIDOS RECUBIERTOS CON PELÍCULA, Hidroxil B1-B6-B12 comprimidos recubiertos con película, Zyvoxid 600 mg Filmtabletten

    The George Institute

    Bacilliferous pulmonary tuberculosis

    phase 2 small molecule active

    1 trial

  2. Rubraca 300 mg film-coated tablets, Rubraca 200 mg film-coated tablets, BEVACIZUMAB, Rubraca 250 mg film-coated tablets, CARBOPLATIN, PACLITAXEL

    Fondazione Telethon ETS

    Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

    phase 2 small molecule active

    1 trial

  3. Ruxolitinib 5 MG BID Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

    phase 2 small molecule active

    1 trial

  4. Rybelsus 7 mg tablets, Kerendia 20 mg film-coated tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  5. Rybelsus 9 mg tablets, Rybelsus 1.5 mg tablets, Rybelsus 4 mg tablets, RO7795081, Rybelsus 7 mg tablets, RO7795081, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets, RO7795081, oral GLP-1R agonist (CT-996) Capsule, hard 0 mg / 1 EA - F10

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2D)

    phase 2 small molecule active

    1 trial

  6. SAR439859, Verzenios 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, Verzenios 150 mg film-coated tablets, IBRANCE 75 mg hard capsules, Verzenios 50 mg film-coated tablets, IBRANCE 100 mg hard capsules

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  7. SCD-044 Tablets 0.1mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 0.3mg, SCD-044 Tablets 1.0mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    atopic dermatitis

    phase 2 small molecule active

    1 trial

  8. SCD-044 Tablets 0.3mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 1.0mg, SCD-044 Tablets 0.1mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    moderate to severe plaque psoriasis

    phase 2 small molecule active

    1 trial

  9. SIKLOS PAEDIATRIC 50mg dispersible tablets

    THERAVIA

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  10. SILIMARIN 200 mg compresse rivestite, Kisqali 200 mg film-coated tablets

    Fondazione Telethon ETS

    hormone receptor positive, HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  11. SPRYCEL 70 mg film-coated tablets, Venetoclax, SPRYCEL 100 mg film-coated tablets, Venetoclax, SPRYCEL 20 mg film-coated tablets, Venetoclax, SPRYCEL 50 mg film-coated tablets, Venetoclax, Venetoclax, Venetoclax, SPRYCEL 10 mg/mL powder for oral suspension

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  12. SUB01423MIG, SUB01423MIG, Colesevelam-matching placebo film-coated oral tablets (Unit Dose C)., Colesevelam-matching placebo film-coated oral tablets (Unit Dose D)., DISSENTEN 2 mg compresse

    Monte Rosa Therapeutics

    Bile acid diarrhoea

    phase 2 small molecule active

    1 trial

  13. Saruparib, ZYTIGA 500 mg film-coated tablets, Erleada 60 mg film-coated tablets, Saruparib, Xtandi - 40 mg soft capsules, Prednisone Mylan Pharma 5 mg compresse, NUBEQA 300 mg film-coated tablets, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  14. Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib

    AstraZeneca AB

    EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  15. Savolitinib, TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets

    AstraZeneca AB

    EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Scemblix 20 mg film-coated tablets, Tasigna 200 mg hard capsules, Scemblix 40 mg film-coated tablets, Tasigna 150 mg hard capsules

    Novartis Pharmaceuticals

    Chronic myeloid leukemia

    phase 2 small molecule active

    1 trial

  17. Scemblix 40 mg film-coated tablets

    Novartis Pharmaceuticals

    CML-CP or CML-AP patients with T315I mutation

    phase 2 small molecule active

    1 trial

  18. Scemblix 40 mg film-coated tablets, Scemblix 40 mg film-coated tablets, Scemblix 20 mg film-coated tablets, Scemblix 40 mg film-coated tablets, NILOTINIB, NILOTINIB, Scemblix 20 mg film-coated tablets, IMATINIB, IMATINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response

    phase 2 small molecule active

    1 trial

  19. Selinexor 20 MG Oral Tablet

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  20. Serlopitant Tablet

    VYNE Therapeutics

    Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial

  21. Sildenafil 50 mg Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Erectile Dysfunction

    phase 2 small molecule completed

    1 trial

  22. Stivarga 40 mg film-coated tablets

    Istituto Gentili S.r.l.

    grade 1, 2 and 3 meningioma

    phase 2 small molecule active

    1 trial

  23. Stivarga 40 mg film-coated tablets

    Ningbo Cancer Hospital

    Bone sarcoma

    phase 2 small molecule active

    1 trial

  24. Stivarga 40 mg film-coated tablets, Tevimbra 100 mg concentrate for solution for infusion, OMTX705

    Lacuna Pharma Pty Ltd

    Advanced/metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources